Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

V2 Trial: A Phase I Study of Venetoclax Combined with CPX-351 for Children, Adolescents and Young Adults with Relapsed or Refractory Acute Leukemia

Laura Agresta, MD, Maureen M O'Brien, MD, Kana Mizuno, PhD, Robin Norris, MD MS, MPH, Erin H. Breese, MD PhD, Christine L Phillips, MD, Karen Burns, MD, Benjamin Mizukawa, Lynn Lee, MD, Adam Lane, PhD, Robert B. Lorsbach, MD PhD, Thomas D. Ryan, MD PhD, Pankaj B. Desai, PhD, Alexander A. Vinks, PharmD, PhD, H. Leighton Grimes, PhD, John P Perentesis, Michael J. Absalon, MD PhD

Blood (2019) 134 (Supplement_1): 3830.

https://doi.org/10.1182/blood-2019-121514

Published: 2019

Journal Articles

A Phase I/Pilot Study of CPX-351 [Daunorubicin and Cytarabine Liposome for Injection (Vyxeos®)] for Children, Adolescents and Young Adults with Recurrent or Refractory Acute Leukemia

Michael J. Absalon, MD PhD, Erin H. Breese, MD PhD, Lynn Lee, MD, Maureen M O'Brien, MD MS, Christine L Phillips, MD, Karen Burns, MD, Benjamin Mizukawa, MD, Qi An, Jennifer Mangino, MD, Joel Kaplan, DO, Robin Norris, MD, John Peter Perentesis, MD

Blood (2018) 132 (Supplement 1): 336.

https://doi.org/10.1182/blood-2018-99-119618

Published: 2018

Journal Articles

In Vitro Approach for the Identification of Exceptional Responders in Acute Myeloid Leukemia

Eric O'Brien, BSc, Brett VanCauwenbergh, BSc, Luke Byerly, BSc, Alexander Merk, BSc, Mayur Sarangdhar, PhD, Mark Wunderlich, MS, Mitali Basu, MSc, Benjamin Mizukawa, MD, Erin H. Breese, MD PhD, William Seibel, PhD, John Peter Perentesis, MD

Blood (2018) 132 (Supplement 1): 2212.

https://doi.org/10.1182/blood-2018-99-116650

Published: 2018

Journal Articles

Predicting Drug Response and Novel Therapeutic Candidates Using Signatures of Molecular Alterations in Hematologic Malignancies

Guillaume Labilloy, MS, Eric O'Brien, BSc, Brett VanCauwenbergh, BSc, Luke Byerly, BSc, Mitali Basu, MSc, William Seibel, PhD, Erin H. Breese, MD PhD, John Peter Perentesis, MD, Mayur Sarangdhar, PhD

Blood (2018) 132 (Supplement 1): 2219.

https://doi.org/10.1182/blood-2018-99-119933

Published: 2018

Journal Articles

Exceptional Responses to Epigenetic Based Therapy in Pediatric and Young Adult Monosomy 7 MDS/AML Patients with and without TP53 Mutations

LaQuita M Jones, DO, Maureen M O'Brien, MD, Erin H. Breese, MD PhD, Karen Burns, MD, Jennifer Mangino, MD, Michael J. Absalon, MD PhD, Javier A. El-Bietar, MD, Michael Grimley, MD, Benjamin Mizukawa, MD, Lynn Lee, MD, John Peter Perentesis, MD, Christine L Phillips, MD

Blood (2017) 130 (Supplement 1): 3895.

https://doi.org/10.1182/blood.V130.Suppl_1.3895.3895

Published: 2017

Journal Articles

Using Genome Engineering To Prospectively Investigate The Pathogenesis Of MLL Translocations In Infant Acute Lymphoblastic Leukemia

Erin H. Breese, MD, PhD, Catherine Dawson, Corina Buechele, MD, Marcus R. Breese, PhD, Michael L. Cleary, MD, Matthew H. Porteus, MD, PhD

Blood (2013) 122 (21): 3722.

https://doi.org/10.1182/blood.V122.21.3722.3722

Published: 2013

NARROW

V2 Trial: A Phase I Study of Venetoclax Combined with CPX-351 for Children, Adolescents and Young Adults with Relapsed or Refractory Acute Leukemia

A Phase I/Pilot Study of CPX-351 [Daunorubicin and Cytarabine Liposome for Injection (Vyxeos®)] for Children, Adolescents and Young Adults with Recurrent or Refractory Acute Leukemia

In Vitro Approach for the Identification of Exceptional Responders in Acute Myeloid Leukemia

Predicting Drug Response and Novel Therapeutic Candidates Using Signatures of Molecular Alterations in Hematologic Malignancies

Exceptional Responses to Epigenetic Based Therapy in Pediatric and Young Adult Monosomy 7 MDS/AML Patients with and without TP53 Mutations

Using Genome Engineering To Prospectively Investigate The Pathogenesis Of MLL Translocations In Infant Acute Lymphoblastic Leukemia

Email alerts

ASH Publications

American Society of Hematology

V2 Trial: A Phase I Study of Venetoclax Combined with CPX-351 for Children, Adolescents and Young Adults with Relapsed or Refractory Acute Leukemia

A Phase I/Pilot Study of CPX-351 [Daunorubicin and Cytarabine Liposome for Injection (Vyxeos®)] for Children, Adolescents and Young Adults with Recurrent or Refractory Acute Leukemia

In Vitro Approach for the Identification of Exceptional Responders in Acute Myeloid Leukemia

Predicting Drug Response and Novel Therapeutic Candidates Using Signatures of Molecular Alterations in Hematologic Malignancies

Exceptional Responses to Epigenetic Based Therapy in Pediatric and Young Adult Monosomy 7 MDS/AML Patients with and without TP53 Mutations

Using Genome Engineering To Prospectively Investigate The Pathogenesis Of MLL Translocations In Infant Acute Lymphoblastic Leukemia

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only